TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

TuHURA Biosciences (NASDAQ: HURA) announced that CEO Dr. James Bianco will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 at 3:20 pm ET. A live and archived webcast will be available via the company's investor relations website.

News Market Reaction – HURA

+7.75%

17 alerts

+7.75% Session close to close

+6.2% Peak Tracked

-19.2% Trough Tracked

$94.11M Market Cap

0.5x Rel. Volume

In the Feb 12 session, HURA gained 7.75%, reflecting a notable positive market reaction. Argus tracked a peak move of +6.2% during that session. Argus tracked a trough of -19.2% from its starting point during tracking. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +7.8% in the session following this news. A strong positive reaction aligns with TuH...

Analysis

The stock moved +7.8% in the session following this news. A strong positive reaction aligns with TuHURA’s push to increase visibility as a Phase 3 immuno-oncology company. Prior catalysts like FDA Orphan Drug Designation and ASH data sometimes produced mixed price follow-through, so historical patterns show both alignment and divergence. With an active shelf registering up to $250,000,000 of securities and a $50,000,000 ATM component, investors have historically faced financing-related overhang that could influence the durability of outsized gains.

Key Figures

Conference edition: 36th Annual Development stage: Phase 3 Presentation date: February 26, 2026 +1 more

4 metrics

Conference edition 36th Annual Oppenheimer Healthcare Life Sciences Conference

Development stage Phase 3 TuHURA described as a Phase 3 immuno-oncology company

Presentation date February 26, 2026 Scheduled conference presentation date

Presentation time 3:20 pm ET Scheduled presentation time at conference

Historical Context

5 past events · Latest: Feb 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 02	Regulatory designation	Positive	-3.0%	FDA Orphan Drug Designation for IFx-2.0 in cutaneous melanoma.
Dec 15	Clinical milestone/CVR	Positive	-6.0%	Kintara REM-001 trial met safety endpoint, triggering CVR share release.
Dec 11	Corporate update/financing	Positive	+0.5%	Corporate update outlining IFx-2.0 trial, pipeline and $15.6M financing.
Dec 08	Preclinical data	Positive	+2.1%	ASH data on Delta Opioid Receptor antagonists overcoming immune resistance.
Nov 14	Earnings/liquidity	Negative	+0.5%	Q3 loss, low cash, going-concern disclosure and financing/ATM plans.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news often showed price divergence: several objectively positive catalysts were followed by negative price reactions, while a weak earnings/liquidity update saw a small gain.

Recent Company History

Over the past few months, TuHURA reported several key milestones. On Nov 14, 2025, Q3 results highlighted higher R&D spend, liquidity concerns, and a planned $50M ATM program. Subsequent disclosures detailed pro forma merger impacts with Kineta and Kintara. In December, the company showcased Delta Opioid Receptor data and issued a corporate update following financing. A Kintara CVR milestone triggered share releases, and on Feb 2, 2026 TuHURA received FDA Orphan Drug Designation for IFx-2.0. Today’s conference presentation notice fits into an ongoing investor-relations and visibility effort.

Key Terms

immuno-oncology, cancer immunotherapy

2 terms

immuno-oncology medical

"TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" ), a Phase 3 immuno-oncology company developing..."

Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.

cancer immunotherapy medical

"developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced..."

Cancer immunotherapy is a group of treatments that help the body’s immune system recognize and attack cancer cells, like training the body’s soldiers to spot a hidden enemy. It matters to investors because these therapies can transform patient outcomes and create large markets if shown safe and effective, so clinical trial results, regulatory approvals, and manufacturing scale can drive significant changes in a company’s revenue and stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TAMPA, Fla., Feb. 12, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that Dr. James Bianco, President and Chief Executive Officer of TuHURA Biosciences, will present at the Oppenheimer 36^th Annual Healthcare Life Sciences Conference.

Date: February 26, 2026
Time: 3:20 pm ET
Links: To register and view presentation, click HERE

A live and archived webcast of the presentation will be available through the investors page of TuHURA's corporate website at https://ir.tuhurabio.com/news-events/events.

About TuHURA Biosciences, Inc. 
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer.

TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA has initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

In addition to its innate immune agonist product candidates, TuHURA acquired TBS-2025 in its merger with Kineta Inc. on June 30, 2025. TBS-2025 is a VISTA inhibiting mAb moving into Phase 2 development in mutNPM1 r/r AML. In addition, TuHURA is leveraging its Delta Opioid Receptor technology to develop first-in-class, bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

For more information, please visit www.tuhurabio.com and connect with TuHURA on Facebook, X, and LinkedIn.

Investor Contact: 
Monique Kosse
Gilmartin Group
Monique@GilmartinIR.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/tuhura-biosciences-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference-302686189.html

SOURCE TuHURA Biosciences, Inc.

FAQ

When will TuHURA (HURA) present at the Oppenheimer conference?

TuHURA will present on February 26, 2026 at 3:20 pm ET. According to the company, Dr. James Bianco will deliver the presentation and a live and archived webcast will be available on the investor relations website.

How can investors watch TuHURA's (HURA) presentation at the February 26, 2026 conference?

Investors can view a live webcast and archived replay on the company's investor relations site. According to the company, register via the conference links and access the presentation page at TuHURA's IR events section.

Who is presenting for TuHURA (HURA) at the Oppenheimer Healthcare Life Sciences Conference?

Dr. James Bianco, TuHURA's President and CEO, will present at the conference. According to the company, he will discuss the company's clinical and corporate developments during the scheduled presentation slot.

What topics will TuHURA (HURA) likely cover during the February 26, 2026 presentation?

The company will present corporate and clinical updates relevant to its Phase 3 immuno-oncology programs. According to the company, the presentation aims to inform investors about development progress and strategic priorities.

Where can I find the archived webcast of TuHURA's (HURA) presentation after February 26, 2026?

The archived webcast will be posted on TuHURA's investor relations news and events page. According to the company, a replay will remain available through the company's IR website after the live presentation.